Research programme: anticancer antibodies - Corixa/Japan Tobacco
Latest Information Update: 22 Mar 2007
At a glance
- Originator Corixa Corporation; Japan Tobacco
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Lung cancer; Solid tumours
Most Recent Events
- 17 Jul 2001 Preclinical development for Lung cancer in Japan (Unknown route)
- 17 Jul 2001 Preclinical development for Lung cancer in USA (Unknown route)
- 17 Jul 2001 Preclinical development for Solid tumours in Japan (Unknown route)